SILO Commends Federal Push for Psychedelic Mental Health Therapies
Silo Pharma, Inc. (SILO) commended recent coordinated U.S. federal actions accelerating the development of psychedelic-based therapeutics for mental health and substance use disorders. These initiatives include ARPA-H awards to institutions like Johns Hopkins for psychedelic science, FDA IND clearance for DemeRx NB's noribogaine, and FDA Commissioner’s National Priority Vouchers for companies like Compass Pathways. Silo Pharma believes this federal focus validates its data-driven approach to treating neurological and psychiatric conditions, including its own SPC-15 for PTSD. The company anticipates imminent final FDA guidance for psychedelic drug development, which is expected to provide critical clarity for the sector.
Key Highlights
- Federal actions accelerate psychedelic-based therapeutics for mental health.
- ARPA-H awarded initial EVIDENT program funds to Johns Hopkins and other innovators.
- FDA granted IND clearance to DemeRx NB for noribogaine targeting alcohol use disorder.
- FDA issued 3 Commissioner’s National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics.
- FDA guidance for psychedelic drug development expected imminently.
- SILO views federal initiatives as validation for its approach to neurological conditions.
- SILO's pipeline includes SPC-15 for PTSD and SP-26 for fibromyalgia.
Price Impact
More from SILO